Vect-Horus

VECT-HORUS has developed a breakthrough technology platform “VECTrans®” based on the design and development of ligands that facilitate the targeted delivery of therapeutic or imaging agents into the brain and other organs.​ ​ By conjugating pharmaceutical agents to its ligands, also called vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules.​ ​ Based on its potential to target specific receptors, notably those that are found at high levels in some pathological tissues, VECT-HORUS is also targeting cancers (pancreatic, adrenal cancer, glioblastoma, etc.), where there is a high unmet medical need and other organs including skeletal and cardiac muscle.​ ​

Vect-Horus’ business model is based on partnering with pharma and biotech companies to vectorize their therapeutic molecules which have not demonstrated expected effects due to e.g. limited brain uptake. Following the proof-of concept studies, Vect-Horus’ strategy is to out-license its vectors to the partner, which will further conduct the drug development process. The licensing agreements generate revenues that fund Vect-Horus’ technology and its development programs.​